Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents
Sponsor: Federal University of São Paulo
Summary
Evaluate the efficacy and safety of subcutaneous ketamine added to usual treatment in the management of depressive episodes with suicidal ideation or behavior in adolescent patients, compared to usual treatment added to placebo (midazolam).
Key Details
Gender
All
Age Range
12 Years - 19 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-05
Completion Date
2028-04
Last Updated
2025-05-04
Healthy Volunteers
No
Conditions
Interventions
ketamine
Ketamine will be administered as adjunctive therapy at an initial dose of 0.5 mg/kg via subcutaneous injection, twice weekly for four weeks, under double-blind conditions. Dose adjustments between 0.5 and 1.0 mg/kg will be based on depressive symptoms, efficacy, and tolerability. All procedures will occur at the Ketamine Clinic of Federal University of São Paulo.
Midazolam
Midazolam will be administered subcutaneously twice weekly for four consecutive weeks, also under double-blind conditions. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.